NCT06628206 - Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

September 15, 2025

Study Completion Date

January 15, 2026

Conditions

Rheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)

Interventions

DRUG

LPX-TI641

Oral solution administered QD for 28 consecutive days

DRUG

Placebo

Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.

Trial Locations (1)

RECRUITING

Triumpharma Clinical Research Unit at AlEssra Hospital, Amman